Search Results

With prostate-specific antigen (PSA) velocity, as in all areas of clinical research, the first question should be, “What is the question?” It cannot reasonably be doubted that PSA velocity is statistically associated with prostate cancer outcomes

Background Initial treatment of prostate cancer is driven by clinical risk factors, including T stage, Gleason score, and prostate-specific antigen (PSA) level, in addition to assessment of regional nodal or distant spread. 1 In men with

Although prostate cancer screening with prostate-specific antigen (PSA) has been shown to reduce metastases and mortality from prostate cancer, 1 , 2 its use has numerous drawbacks. A key issue is its limited specificity for clinically

T he prostate-specific antigen (PSA) blood test is the foundation for modern prostate cancer (CaP) screening. Initially it was used in forensic medicine. The subsequent discovery that it could be measured in serum, and that serum levels increase

The year 2012 marks the 10th anniversary of the initial reporting of active surveillance (AS) as a management strategy for low-risk prostate cancer. 1 , 2 Since the widespread use of prostate-specific antigen (PSA) beginning in the early 1990s

deprivation therapy (ADT) are often curative treatments for localized disease, 2 – 5 approximately one-quarter of patients will experience recurrence within 10 years after curative-intent therapy. 6 , 7 An increasing prostate-specific antigen (PSA) level

during the patient’s lifetime. Autopsy studies detect prostate cancer in 30% of men by age 55 years and 60% of men by age 80 years. 3 Widespread implementation of prostate-specific antigen (PSA) screening has led to a significant increase in diagnosis

. CA Cancer J Clin 2003 ; 53 : 5 – 26 . 2 Catalona WJ Smith DS Ratliff TL . Measurement of prostate-specific antigen in serum as a screening test for prostate cancer . N Engl J Med 1991 ; 324 : 1156 – 1161 . 3 Babaian RJ

conferred the same toxicity as orchiectomy. After the test for prostate-specific antigen (PSA) was approved by the FDA in 1986, a new population of men was identified who had no evidence of metastatic disease other than an increasing PSA level after primary

figure out which treatment is best for the patient?” he said. Figure 1. An example of patient preference–based dialogue for recommendations. Abbreviation: PSA, prostate-specific antigen. The Typical Conversation Dr. Ubel said that